Publications by authors named "Ina Rhee"

Claim this Profile
R
RNA neoantigen vaccines prime long-lived CD8 T cells in pancreatic cancer.
Zachary Sethna, Pablo Guasp, Charlotte Reiche, Martina Milighetti, Nicholas Ceglia, Ina Rhee

Nature· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial.
Juanita Lopez, Thomas Powles, Fadi Braiteh, Lillian L Siu, Patricia LoRusso, Ina Rhee

Nat Med· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.
Luis A Rojas, Zachary Sethna, Kevin C Soares, Cristina Olcese, Nan Pang, Ina Rhee

Nature· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy.
Naiyer Rizvi, Foluso O Ademuyiwa, Z Alexander Cao, Helen X Chen, Robert L Ferris, Ina Rhee

J Immunother Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors.
Tae Won Kim, Howard A Burris, Maria J de Miguel Luken, Michael J Pishvaian, Yung-Jue Bang, Ina Rhee

Clin Cancer Res· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.
Kyung Hae Jung, Patricia LoRusso, Howard Burris, Michael Gordon, Yung-Jue Bang, Ina Rhee

Clin Cancer Res· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors.
Colin D Weekes, Lee S Rosen, Anna Capasso, Kit Man Wong, Weilan Ye, Ina Rhee

Cancer Chemother Pharmacol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer.
Joachim von Pawel, David R Spigel, Thomas Ervin, György Losonczy, Fabrice Barlesi, Ina Rhee

Oncologist· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy.
F Stephen Hodi, Marcus Ballinger, Benjamin Lyons, Jean-Charles Soria, Mizuki Nishino, Ina Rhee

J Clin Oncol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.
Rocío García-Carbonero, Eric van Cutsem, Fernando Rivera, Jacek Jassem, Ira Gore, Ina Rhee

Oncologist· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.
Rocío García-Carbonero, Eric van Cutsem, Fernando Rivera, Jacek Jassem, Ira Gore, Ina Rhee

Oncologist· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical translation of ferumoxytol-based vessel size imaging (VSI): Feasibility in a phase I oncology clinical trial population.
Jill Fredrickson, Natalie J Serkova, Shelby K Wyatt, Richard A D Carano, Andrea Pirzkall, Ina Rhee

Magn Reson Med· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
De novo CpG island methylation in human cancer cells.
Kam-Wing Jair, Kurtis E Bachman, Hiromu Suzuki, Angela H Ting, Ina Rhee

Cancer Res· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene.
Kurtis E Bachman, Ben Ho Park, Ina Rhee, Harith Rajagopalan, James G Herman

Cancer Cell· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DNMT1 and DNMT3b cooperate to silence genes in human cancer cells.
Ina Rhee, Kurtis E Bachman, Ben Ho Park, Kam-Wing Jair, Ray-Whay Chiu Yen

Nature· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis